Alzheimer's disease amyloid hypothesis at crossroads: Where do we go from here?

Expert Opinion on Therapeutic Targets

Volumn 14, Issue 12, 2010, Pages 1273-1277

  Saxena, Uday ^a  

^a Kareus Therapeutics   (Switzerland)

Author keywords

Alzheimer's disease; amyloid hypothesis; disease modifying drugs; neuronal energy; neuronal oxidative stress

Indexed keywords

ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; BETA SECRETASE; FLURBIPROFEN; GAMMA SECRETASE; HOMOTAURINE; SEMAGACESTAT; TARENFLURBIL;

AGING; ALZHEIMER DISEASE; CANCER RISK; CLINICAL TRIAL; COGNITIVE DEFECT; DRUG EFFICACY; DRUG TREATMENT FAILURE; HUMAN; MENINGOENCEPHALITIS; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PROTEIN AGGREGATION; REVIEW; RISK FACTOR; SIDE EFFECT; SKIN CANCER; STROKE; TRAUMATIC BRAIN INJURY;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; CLINICAL TRIALS AS TOPIC; DRUG DISCOVERY; HUMANS; OXIDATIVE STRESS; PLAQUE, AMYLOID; RISK FACTORS;

EID: 78249257305     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.2010.528285     Document Type: Review

References (20)

1. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002;297:353-6
2. Aisen PS, Gauthier S, Vellas B, et al. Alzhemed: a potential treatment for Alzheimer's disease. Curr Alzheimer Res 2007;4(4):473-8
3. Aisen PS, Saumier D, Briand R, et al. A Phase II study targeting amyloid-beta with 3APS in mild-to-moderate Alzheimer disease. Neurology 2006;67:1757-63
4. Relkin NR. Current state of immunotherapy for Alzheimer's disease. CNS Spectr 2008;13:39-41
5. Gilman S, Koller M, Black RS, et al. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 2005;64:1553-62
6. Eriksen JL, Sagi SA, Smith TE, et al. NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta42 in vivo. J Clin Invest 2003;112:440-1
7. Wilcock GK, Black SE, Hendrix SB, et al. Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial. Lancet Neurol 2008;7:483-93
8. Fleisher AS, Raman R, Siemers ER, et al. Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease. Arch Neurol 2008;65(8):1031-8
9. Lilly Halts Development of Semagacestat for Alzheimer's disease based on preliminary results of Phase III Clinical Trials. Lilly Press release, Indianapolis, IN: Eli Lilly and Company, 17 August 2010. Available from: www.lilly.com [Last accessed 8 October 2010]
10. Yao J, Irwin RW, Zhao L, et al. Mitochondrial bioenergetic deficit precedes Alzheimer's pathology in female mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 2009;106(34):14670-5
11. Mosconi L, Pupi A, De Leon MJ. Brain glucose hypometabolism and oxidative stress in preclinical Alzheimer's disease. Ann NY Acad Sci 2008;1147:180-95
12. Mosconi L, Mistur R, Switalski R, et al. FDG-PET changes in brain glucose metabolism from normal cognition to pathologically verified Alzheimer's disease. Eur J Nucl Med Mol Imaging 2009;36(5):811-22
13. Mosconi L. Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. FDG-PET studies in MCI and AD. Eur J Nucl Med Mol Imaging 2005;32(4):486-510
14. Sultana R, Perluigi M, Butterfield DA. Oxidatively modified proteins in Alzheimer's disease (AD), mild cognitive impairment and animal models of AD: role of Abeta in pathogenesis. Acta Neuropathol 2009;118(1):131-50
15. Quiroz-Baez R, Rojas E, Arias C. Oxidative stress promotes JNK-dependent amyloidogenic processing of normally expressed human APP by differential modification of alpha-, beta-and gamma-secretase expression. Neurochem Int 2009;55(7):662-70
16. Shen C, Chen Y, Liu H, et al. Hydrogen peroxide promotes Abeta production through JNK-dependent activation of gamma-secretase. J Biol Chem 2008;283(25):17721-30
17. Vassar R, Kovacs DM, Yan R, Wong PC. The beta-secretase enzyme BACE in health and Alzheimer's disease: regulation, cell biology, function, and therapeutic potential. J Neurosci 2009;29(41):12787-94
18. Tong Y, Zhou W, Fung V, et al. Oxidative stress potentiates BACE1 gene expression and Abeta generation. J Neural Transm 2005;112(3):455-69
19. Xiong K, Cai H, Luo XG, et al. Mitochondrial respiratory inhibition and oxidative stress elevate beta-secretase (BACE1) proteins and activity in vivo in the rat retina. Exp Brain Res 2007;181(3):435-46
20. Velliquette RA, O'Connor T, Vassar R. Energy inhibition elevates beta-secretase levels and activity and is potentially amyloidogenic in APP transgenic mice: possible early events in Alzheimer's disease pathogenesis. J Neurosci 2005;25(47):10874-83